Clinical Trial Update: Busulfan, Melphalan, and Fludarabine With Peri-transplant Palifermin, Followed by a T-Cell Depleted Hematopoietic Stem Cell Transplant From HLA Matched or Mismatched Related or Unrelated Donors in Patients With Advanced Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating a conditioning regimen (busulfan, melphalan, fludarabine) with peri-transplant palifermin followed by T-cell depleted hematopo…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Myelodysplastic Syndromes

Drugs mentioned

• Palifermin (palifermin)
• busulfan, melphalan, and fludarabine regimen

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Acute Myeloid Leukemia, Advanced Myelodysplastic Syndromes | Phase 2 | Status: COMPLETED | Results posted: 2021-09-24